Projects per year
Fingerprint Dive into the research topics where Yiyu Zou is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Liposomes
Medicine & Life Sciences
Doxorubicin
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Hepatic Artery
Medicine & Life Sciences
Anthracyclines
Medicine & Life Sciences
Heterografts
Medicine & Life Sciences
Non-Small Cell Lung Carcinoma
Medicine & Life Sciences
Tumors
Chemical Compounds
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Grants 2006 2018
- 2 Finished
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy
Zou, Y., Perez-Soler, R., Perez-Soler, R., Zou, Y. & Perez-Soler, R.
2/15/11 → 1/31/18
Project: Research project
Azacitidine
Genetic Therapy
Lung Neoplasms
Lung
Epithelium
A Tumor Specific Therapy Approach for Small Cell Lung Cancer
7/1/06 → 6/30/10
Project: Research project
Small Cell Lung Carcinoma
Neoplasms
Genes
Therapeutics
Gene Expression
Publications 1989 2019
1
Citation
(Scopus)
Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma
Shenoy, N., Bhagat, T. D., Cheville, J., Lohse, C., Bhattacharyya, S., Tischer, A., Machha, V., Gordon-Mitchell, S., Choudhary, G., Wong, L. F., Gross, L. A., Ressigue, E., Leibovich, B., Boorjian, S. A., Steidl, U., Wu, X., Pradhan, K., Gartrell, B., Agarwal, B., Pagliaro, L. & 8 others, , Apr 1 2019, In : Journal of Clinical Investigation. 129, 4, p. 1612-1625 14 p.Research output: Contribution to journal › Article
Open Access
Renal Cell Carcinoma
Ascorbic Acid
Methylation
Cytosine
Protein Transport
1
Citation
(Scopus)
PAK kinase inhibition has therapeutic activity in novel preclinical models of adult T-Cell leukemia/lymphoma
Chung, E. Y. L., Mai, Y., Shah, U. A., Wei, Y., Ishida, E., Kataoka, K., Ren, X., Pradhan, K., Bartholdy, B. A., Wei, X., Zou, Y., Zhang, J., Ogawa, S., Steidl, U. G., Zang, X., Verma, A. K., Janakiram, M. & Ye, B. H., Jun 15 2019, In : Clinical Cancer Research. 25, 12, p. 3589-3601 13 p.Research output: Contribution to journal › Article
p21-Activated Kinases
Adult T Cell Leukemia Lymphoma
Therapeutics
Cell Survival
Protein Isoforms
7
Citations
(Scopus)
Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer
Bhagat, T. D., Zou, Y., Huang, S., Park, J., Palmer, M. B., Hu, C., Li, W., Shenoy, N., Giricz, O., Choudhary, G., Yu, Y., Ko, Y. A., Izquierdo, M. C., Park, A. S. D., Vallumsetla, N., Laurence, R., Lopez, R., Suzuki, M., Pullman, J., Kaner, J. & 8 others, , Jan 20 2017, In : Journal of Biological Chemistry. 292, 3, p. 837-846 10 p.Research output: Contribution to journal › Article
Renal Cell Carcinoma
Epigenomics
Chemical activation
Tumors
Cells
1
Citation
(Scopus)
Pax5 Re-expression in H460 cells treated with the combination of demethylating agent and histone deacetylase inhibitor is associated with the enhancement of P53 binding to Pax5 promoter region
Liang, Y., Zeng, J., Jelicks, L., Ma, S., Liu, J., Mei, J., Perez-Soler, R. & Zou, Y., Feb 1 2017, In : Current Cancer Drug Targets. 17, 2, p. 169-176 8 p.Research output: Contribution to journal › Review article
Azacitidine
Histone Deacetylase Inhibitors
Genetic Promoter Regions
Non-Small Cell Lung Carcinoma
Transcription Factors
TRIB2 contributes to cisplatin resistance in small cell lung cancer
Liang, Y., Yu, D., Perez-Soler, R., Klostergaard, J. & Zou, Y., Jan 1 2017, In : Oncotarget. 8, 65, p. 109596-109608 13 p.Research output: Contribution to journal › Article
Small Cell Lung Carcinoma
Cisplatin
CCAAT-Enhancer-Binding Protein-alpha
Neoplastic Stem Cells
Proteins